Rare Disease ReportCRISPR Used to Disable Defective Gene in ALSRare Disease ReportIn historical studies, CRISPR/Cas9 technology has exhibited the ability to decrease the functionality of the mutant Dystrophin protein which has long been believed to be … Continue reading
|
Cellect Bio’s ApoGraft stem cells completely accepted by first blood cancer patients in Phase 1/2 study; shares up …
Seeking Alpha Thinly traded nano cap Cellect Biotechnology (NASDAQ:APOP) is up 86% premarket on robust volume in response to encouraging results in a Phase 1/2 clinical trial assessing ApoGraft-processed donor-derived peripheral blood cells transplanted into blood … Cellect (APOP) Says First Group of Patients in Clinical Trial With its ApoGraft Stem Cell Transplant Follow up …StreetInsider.com UPDATE: Cellect Biotech shares rocket 65% premarket after unveiling stem cell breakthroughForexTV.com |
|
Cellect Bio’s ApoGraft stem cells completely accepted by first blood cancer patients in Phase 1/2 study; shares up …
Seeking Alpha Thinly traded nano cap Cellect Biotechnology (NASDAQ:APOP) is up 86% premarket on robust volume in response to encouraging results in a Phase 1/2 clinical trial assessing ApoGraft-processed donor-derived peripheral blood cells transplanted into blood … Cellect (APOP) Says First Group of Patients in Clinical Trial With its ApoGraft Stem Cell Transplant Follow up …StreetInsider.com Cellect Biotechnology | $APOP Stock | Shares Surge On Positive Stem Cell TrialWarrior Trading News (press release) UPDATE: Cellect Biotech shares rocket 65% premarket after unveiling stem cell breakthroughForexTV.com |
|
Audentes’ gene therapy AT132 shows positive effect in XLMTM study; shares ahead 13% premarket
Seeking Alpha Thinly traded Audentes Therapeutics (NASDAQ:BOLD) is up 13% premarket on light volume in response to its announcement of positive preliminary results from a Phase 1/2 clinical trial, ASPIRO, assessing gene therapy candidate AT132 in patients with X … |